Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BLUE    crawled date : 2021 - 11 - 22    save search
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-11-22 (Crawled : 14:30) - biospace.com/
BLUE | $0.9257 -4.63% 7.3M twitter stocktwits trandingview |
Health Technology
 | | O: 5.7% H: 0.44% C: -6.81%
fda blood transfusion application gene therapy therapy license cel
Gainers vs Losers
58% 42%

Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M twitter stocktwits trandingview |
Consumer Services
CZOO | $11.04 121.24% 11M twitter stocktwits trandingview |

LICN | $0.9107 62.63% 14M twitter stocktwits trandingview |

BOF | $1.87 59.83% 100M twitter stocktwits trandingview |

AMST | $3.18 59.0% 67M twitter stocktwits trandingview |
Technology Services
MTC | $3.31 47.77% 7.7M twitter stocktwits trandingview |
Technology Services
MULN | News | $3.915 43.41% 12M twitter stocktwits trandingview |
Information
WIMI | $1.04 43.37% 17M twitter stocktwits trandingview |
Technology Services
SKIL 4 | $8.045 40.89% 230K twitter stocktwits trandingview |
Information
RILY | $30.01 38.17% 11M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.